Schedule of Activities- Parkinson's Disease (PD) Subjects [Please see modified Schedule of Activities on page 28 for visits post January 1, 2019 or post V15 (whichever is later)]

	Visit Number	SC	BL	V01	V02	V03	V04b	V05b	A06b	V07b	V08b	V09b	V10b	V11b	V12	V13	V14	V15	PW	\mathbf{ST}	Unsch Visit
Visit Description	Months (±30 days)	-45 day	0	3	6	9	12	18	24	30	36	42	48	54	60	72	84	96			
Written Informed Consent		X																			
Consent/Withdrawal of Co Procedures#		X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	
Advance Directive/Review Consent #		X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X		X
Consent to Share Contact I PPMI companion protocol))#	X					X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Consent to Share Contact I Brain and Tissue Bank/Adv Brain and Tissue Bank#†							X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Review Inclusion/Exclusio	n Criteria	X	X																		
Medical & Family History/	Demographics	X																			
Physical Examination		X																			
Neurological Examination		X					X		X		X		X		X	X	X	X	X	Xk	Xg
Vital Signs		X	Xc	X	X	X	Xc	X	Xc	X	X ^c	X	Xc	X	Xc	Xc	Xc	Xc	Xc	X	X
Blood Sample for DNA		X																			
Clinical Laboratory Assess	ments	X					X		X		X		X		X	X	X	X	X	Xk	Xg
Biomic blood sample			Xf	X	Xf	X	X^{f}	X	X^{f}	X	Xf	X	X^{f}	X	Xf	Xf	Xf	Xf	Xf	X^{f}	
PBMC blood sample			X		X			X		X		X		X							
MDS-UPDRS (including H		X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	
Modified Schwab & Engla		X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	
Clinical Diagnosis Assessn		X					X		X		X		X		X	X	X	X	X	X	
MDS-UPDRS Repeat Part							X		X		X		X		X	X	X	X	X		
Physical Activity Scale for							X		X		X		X		X	X	X	X	X		
Hopkins Verbal Learning T			X				X		X		X		X		X	X	X	X	X	X^k	
Benton Judgment of Line C	Orientation		X				X		X		X		X		X	X	X	X	X	X^k	
Semantic Fluency			X				X		X		X		X		X	X	X	X	X	X^k	
Letter Number Sequencing	5		X				X		X		X		X		X	X	X	X	X	X^k	
Symbol Digit Modalities T			X				X		X		X		X		X	X	X	X	X	X^k	
Montreal Cognitive Assess	ment (MoCA)	X					X		X		X		X		X	X	X	X	X	X^k	
Epworth Sleepiness Scale			X		X		X		X		X		X		X	X	X	X	X	X	
REM Sleep Behavior Ques			X		X		X		X		X		X		X	X	X	X	X	X	
Geriatric Depression Scale	(GDS-15)		X		X		X		X		X		X		X	X	X	X	X	X	
State-Trait Anxiety Invento	ory for Adults		X		X		X		X		X		X		X	X	X	X	X	X	
QUIP			X		X		X		X		X		X		X	X	X	X	X	X	
SCOPA-AUT			X		X		X		X		X		X		X	X	X	X	X	X	
Cognitive Categorization			X		X		X		X		X		X		X	X	X	X	X	X^k	

November 20, 2017/Amendment 13

Olfactory Testing (UPSIT)		X																		
MRI (structural)		X																		
MRI (DTI)e		X				X		X				X						^X		
DAT imaging ^{m,o}	X					X		X				X						^X	$\mathbf{X}^{\mathbf{k}}$	
[18F] florbetaben PET imaging (see companion protocol)s								X		(X)		(X)		(X)	(X)	(X)	(X)	(X) +		
VMAT-2 imaging ^{m,o, r} (see companion protocol)	Xp					X		X				X						^X	X^k	
Lumbar puncture (CSF collection)		X		X		X		X		X		X		X	X	X	X	*X	X^k	
Adverse Eventsa	X	X		X		X		X		X		X		X	X	X	X	X	X	
Current Medical Conditions Review		X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Concomitant Medication Review	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Skin Biopsy t (see companion protocol)						X	(+ foll	ow up	call wit	hin 7-10	0 days o	of biops	sy)							X
Blood draw ^t																				X
Sensor-PPMI activities (see companion protocol)										2	X									

ST = Symptomatic Therapy

PW = Premature Withdrawal (*if not done in last 3 mths; ^if not done in last 12 mths; +if subject has not completed scan and is willing to complete at PW)

^a Adverse events assessed at the visit and by phone 7 to 10 days following LP and/or DaTSCAN injection and following skin biopsy and/or [¹⁸F] florbetaben PET imaging (for participating sites).

^b Telephone consent will occur at Months 15, 21, 27, 33, 39, 45, 51 and 57.

^c Height and weight also collected.

^e Diffusion tensor MRI scan and resting state sequences conducted at selected sites.

f Biomic urine sample also collected.

g Conduct as clinically indicated – see protocol Sect. 5.3.18.

^h Part IV once subject has started PD medication.

^j Repeat assessment 1hr post treatment for subjects on levodopa or dopamine agonist.

^k Not conducted depending on when ST visit completed – see protocol Sect. 5.3.20.

^m DAT completed at all sites except Australia; VMAT completed in Australia and selected U.S. sites.

[†] Intent to Donate documentation completed with PPMI Brain and Tissue Bank study team or local PPMI site based on accessibility, local regulations and availability of infrastructure. For subjects who have not yet been approached concerning the Brain and Tissue Bank, please review subject interest in providing permission to forward their contact information to the PPMI Brain and Tissue Bank study team at their next visit (including interim visits). For subjects who may have already been approached concerning the Brain and Tissue Bank, but were undecided concerning participation or who have not yet signed an Intent to Donate form- please review Brain and Tissue Bank with subject at next annual visit (sites may also review this at interim visits if site deems appropriate).

^o Urine (or serum) pregnancy test prior to injection for women of childbearing potential. ^p Serum pregnancy test prior to injection day for women of childbearing potential; ECG

F Serum pregnancy test prior to injection day for women of childbearing potential; ECG for all subjects.

^r Subjects enrolled in U.S. may agree to initial VMAT imaging scan at YR01 rather than Screening. ^s [¹⁸F]

^{*}florbetaben PET imaging at selected sites (see companion protocol) at either Month 24, 36, 48, 60, 72, 84 or 96¹ Skin biopsy for participating sites completed at any routine or unscheduled visit post amendment approval; for sites collecting blood samples as part of companion study, blood draw completed at unscheduled visit post amendment approval. ¹ Skin biopsy for participating sites completed at any routine or unscheduled visit post amendment approval; for sites collecting blood samples as part of companion study, blood draw completed at unscheduled visit or interim visit post amendment approval. (sites completing collection of blood sample at interim visit must forego collection of PBMCs and biomic blood samples at interim visit)

[#] For active subjects, begin at next visit post amendment approval and consent

Schedule of Activities – Healthy Control (HC) Subjects [Please see modified Schedule of Activities on page 28 for visits post January 1, 2019 or post V15 (whichever is later)]

	Visit Number	SC	BL	V01	V02	V03	V04 ^b	V05b	490Л	V07b	480Л	460A	$V10^{b}$	V11b	V12	V13	V14	V15	PW	Unsch. Visit
															-					1
Visit Description	Months (±30 days)	-45 days	0	3	6	9	12	18	24	30	36	42	48	54	60	72	84	96		
Written Informed Consen	t	X																		
Consent/Withdrawal of C Procedures#		X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	
Advance Directive/Revie Consent [#]	w Continuing Ability to	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Consent to Share Contact PPMI companion protoco		X					X	X	X	X	X	X	X	X	X	X	X	X	X	X
Consent to Share Contact Brain and Tissue Bank/A PPMI Brain and Tissue B	dvance Directive for						X	X	X	X	X	X	X	X	X	X	X	X	X	X
Review Inclusion/Exclusion		X	X																	
Medical & Family Histor	y/Demographics	X																		
Physical Examination		X																		
Neurological Examination	n	X					X		X		X		X		X	X	X	X	X	X^g
Vital Signs		X	Xc	X	X	X	Xc	X	Xc	X	Xc	X	Xc	X	Xc	X	Xc	X	Xc	X
Blood Sample for DNA		X																		
Clinical Laboratory Asses	ssments	X					X		X		X		X		X	X	X	X	X	X^g
Biomic blood sample			Xf	X	Xf	X	X^f	X	Xf	X	Xf	X	Xf	X	Xf	Xf	Xf	X^{f}	*Xf	
PBMC blood sample			X		X			X		X		X		X						
MDS-UPDRS (including	<u> </u>		X				X		X		X		X		X	X	X	X	X	
Clinical Diagnosis Assess		X					X		X		X		X		X	X	X	X	X	
Physical Activity Scale for							X		X		X		X		X	X	X	X	X	
Hopkins Verbal Learning			X				X		X		X		X		X	X	X	X	X	
Benton Judgment of Line	Orientation		X				X		X		X		X		X	X	X	X	X	
Semantic Fluency			X				X		X		X		X		X	X	X	X	X	
Letter Number Sequencin			X				X		X		X		X		X	X	X	X	X	
Symbol Digit Modalities			X				X		X		X		X		X	X	X	X	X	
Montreal Cognitive Asses	ssment (MoCA)	X					X		X		X		X		X	X	X	X	X	
Epworth Sleepiness Scale			X				X		X		X		X		X	X	X	X	X	
REM Sleep Behavior Que	estionnaire		X				X		X		X		X		X	X	X	X	X	
Geriatric Depression Scal			X				X		X		X		X		X	X	X	X	X	
State-Trait Anxiety Inven			X				X		X		X		X		X	X	X	X	X	
QUIP	<u> </u>		X				X		X		X		X		X	X	X	X	X	
SCOPA-AUT			X	t			X		X		X	t	X		X	X	X	X	X	
Cognitive Categorization			X	İ			X		X		X	İ	X		X	X	X	X	X	
Olfactory Testing (UPSI)	Γ)		X																	

November 20, 2017/Amendment 13

MRI (structural)		X																	1
MRI (DTI) ^e		X				X		(Xe)		(Xe)		(Xe)		(Xe)				^X	
DAT imaging ^{m,o}	X																		1
[¹⁸ F] florbetaben PET imaging (see companion protocol) ^s								X		(X)		(X)		(X)		(X)		(X) ⁺	
VMAT-2 imaging ^{m,o, r}	X^p																		1
Lumbar puncture (CSF collection)		X		X		X		X		X		X		X	X	X	X	*X	1
Adverse Events ^a	X	X		X		X		X		X		X		X	X	X	X	X	<u> </u>
Current Medical Conditions Review		X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Concomitant Medication Review	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Skin biopsy ^t (see companion protocol)							X (+ fo	llow up	call wit	hin 7-10	days o	f biopsy)						X
Blood draw ^t																			X
Sensor-PPMI activities (see companion protocol)										X									

PW = Premature Withdrawal (*if not done in last 3 mths; ^ only if withdrawal within first 12 mths and MRI DTI not done in last 6 mths)

^a Adverse events assessed at the visit and by phone 7 to 10 days following LP and/or DaTSCAN injection and following skin biopsy and/or [¹⁸F] florbetaben PET imaging (for participating sites).

^b Telephone consent will occur at Months 15, 21, 27, 33, 39, 45, 51 and 57.

^c Height and weight also collected.

^e Diffusion tensor MRI scan and resting state sequences conducted at selected sites.

f Biomic urine sample also collected.

^g Conduct as clinically indicated – see protocol Sect. 5.3.18.

^h Part IV once subject has started PD medication.

^j Repeat assessment 1hr post treatment for subjects on levodopa or dopamine agonist.

^k Not conducted depending on when ST visit completed – see protocol Sect. 5.3.20.

^mDAT completed at all sites except Australia; VMAT completed in Australia and selected U.S. sites.

 $^{^{\}rm o}$ Urine (or serum) pregnancy test prior to injection for women of childbearing potential.

^p Serum pregnancy test prior to injection day for women of childbearing potential.

^r Subjects enrolled in U.S. may agree to initial VMAT imaging scan at YR01 rather than Screening.

^s[¹⁸F] florbetaben PET imaging at selected sites (see companion protocol) at either Month 24, 36, 48, or 60 (what about month 84?)

^t Skin biopsy for participating sites completed at any routine or unscheduled visit post amendment approval; for sites collecting blood samples as part of companion study, blood draw completed at unscheduled visit or interim visit post amendment approval. (sites completing collection of blood sample at interim visit must forego collection of PBMCs and biomic blood samples at interim visit) PV= Phone Visit

[#] For active subjects, begin at next visit post amendment approval and consent

[†] Intent to Donate documentation completed with PPMI Brain and Tissue Bank study team or local PPMI site based on accessibility, local regulations and availability of infrastructure.

Schedule of Activities - SWEDD Subjects

For SWEDDS continuing or returning^s Unsch. Visit $^{\rm p} m C02^{\rm p}$ $V11^b$ V04b $V05^b$ 480 60 $V10^{b}$ Visit Number V02 V03 90 A V01 ΡW BL \mathbf{S} -45 0 3 9 36 48 72 **Visit Description** Months (±30 days) 12 18 24 30 42 54 dav Written Informed Consent X X^{u} Consent/Withdrawal of Consent for Future Procedures# X X X X X X X X X X X X X X X X X X X Advance Directive/Review Continuing Ability to Consent# X X X X X X X X X X X X X X X X X X X X Consent to Share Contact Information (FOUND in PPMI X X X X X X X X X X X X X X companion protocol)# Consent to Share Contact Information with PPMI Brain and Tissue Bank / Advance Directive for PPMI Brain and Tissue X X X X X X X X X X X X X X X Bank #† X X Review Inclusion/Exclusion Criteria X Medical and Family History/Demographics **Physical Examination** X Neurological Examination X X X X X X X X X X X^k \mathbf{X}^{g} X X^{c} X^c Xc X^c X^c X^c Vital Signs X^c X X X X X^c X X^c X X X^{c} X X Clinical Laboratory Assessments X X X X X X X X X X^k Xg Biomic blood sample X^f X X^f X X^f X X^f X X^f X X^f X X^f \mathbf{X}^{f} X^f X^f $*X^f$ X^f X X X X X X X Xv Χ^v Xv Xk Lumbar puncture (CSF collection) *XMDS-UPDRS (including Hoehn & Yahr) h X X X X X X X X X X X X X X X X X X X X X X X X Modified Schwab & England ADL X X X X X X X X X X X X X X MDS-UPDRS Repeat Part III / Hoehn & Yahr^j X X X X X X X X X Clinical Diagnosis and Management Questionnaire X X X X X X X X X Clinical Diagnosis Assessment(s) X X X X X X X X Physical Activity Scale for the Elderly (PASE) X X X X X X X X X Hopkins Verbal Learning Test – Revised X X X X X X X X X X X X Xk Benton Judgment of Line Orientation X X X X X X X X X X X X X X X Xk Semantic Fluency X X X X X X X X X X X X X X Xk Letter Number Sequencing X X X X X X X X X X^k Symbol Digit Modalities Test X Montreal Cognitive Assessment (MoCA) X X X X^k X X X X X X X **Epworth Sleepiness Scale** X X X X X X X X X X X X X X X X REM Sleep Behavior Questionnaire X X X X X X X X X X X X Geriatric Depression Scale (GDS-15) X X X X X х X X State-Trait Anxiety Inventory for Adults X X X X X X X X X X X X **OUIP** X X X X X X X X X X X X SCOPA-AUT X X X X X X X X X X X X X X X X X X X X X X X^k Cognitive Categorization X X Olfactory Testing (UPSIT) MRI (structural) X MRI (DTI)e X X X ^X

DAT imaging ^{m,o}								X				X						^X	X^k	
VMAT-2 imaging ^{m,o, r}								X				X						^X	X^k	
Adverse Events ^a		X		X		X		X		X		X		X	X	X	X	X	X	
Current Medical Conditions and Concomitant Medication Review	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X

- ^a Adverse events assessed at the visit and by phone 7 to 10 days following LP and/or DaTSCAN injection.
- ^b Telephone contact will occur at Months 15 and 21 (for SWEDDS post V06, also at Months 27, 33, 39, 45, 51 and 57).
- ^c Height and weight also collected.
- ^e Diffusion tensor MRI scan and resting state sequences conducted at selected sites.
- ^f Biomic urine sample also collected.
- ^g Conduct as clinically indicated see protocol Sect. 5.3.18.
- ^h Part IV once subject has started PD medication.
- ^j Repeat assessment 1hr post treatment for subjects on levodopa or dopamine agonist.
- [†] For subjects who have not yet been approached concerning the Brain and Tissue Bank, please review subject interest in providing permission to forward their contact information to the PPMI Brain and Tissue Bank study team at their next visit (including interim visits). For subjects who may have already been approached concerning the Brain and Tissue Bank, but were undecided concerning participation or who have not yet signed an Intent to Donate form- please review Brain and Tissue Bank with subject at next annual visit (sites may also review this at interim visits if site deems appropriate).

- ^k Not conducted depending on when ST visit completed see protocol Sect. 5.3.20.
- ^mDAT completed in all sites except Australia; VMAT completed in Australia and selected U.S. sites.
- ^o Urine (or serum) pregnancy test prior to injection for women of childbearing potential.
- ^r Subjects enrolled in U.S. may agree to initial VMAT imaging scan at YR01 rather than Screening.
- ^s For SWEDDs who will continue (or return to) follow up after Month 24.
- ^u Subjects should be re-consented before continuing

ST = Symptomatic Therapy

PW = Premature Withdrawal (*if not done in last 3 mths; ^ if not done in last 12 mths)

For active subjects, begin at next visit post amendment approval and consent

Schedule of Activities – PRODROMAL Subjects [Please see modified Schedule of Activities on page 30 for post month 60 visits]

Sen	edule of Activities – Fr	ODIONI	TILL DUD	Jeeus L	I	1	- Carrie	u Deire	T T	1 110011	10105 0	II puge	7 00 101	post 1	1101111	00 11	100]	1	
	Visit Number	Pre SC	SC	BL	V01	V02	V03	V04 ^b	V05b	_q 90A	V07b	480A	460A	V10b	V11	V12	PW	ST	Unsch. Visit
Visit Description	Months (±30 days)	-6 mths	-45 days	0	3	6	9	12	18	24	30	36	42	48	54	60			
Written Informed Consent		X	X																
Consent/Withdrawal of Consent for Future Procedu	res#	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	
Advance Directive/Review Continuing Ability to C	onsent#		X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Consent to Share Contact Information (FOUND in protocol)#	PPMI companion		X			X	X	X	X	X	X	X	X	X	X	X	X	X	X
Consent to Share Contact Information with PPMI B								X	X	X	X	X	X	X	X	X	X	X	X
/Advance Directive for PPMI Brain and Tissue Ban	K " '	37	37	37															
Review of Inclusion/Exclusion Criteria		X	X	X															
Review of PSG p		X	-																
Self Reporting Questionnaire*		X		37								175							
Olfactory Testing (UPSIT)		X	37	X								X>							
Medical & Family History/Demographics			X																
Physical Examination			X					37		37		37		37		37	37	3.7k	3 70
Neurological Examination			X	370	37	37	37	X	37	X	37	X	37	X	37	X	X	X ^k	Xg
Vital Signs			X	Xc	X	X	X	Xc	X	Xc	X	Xc	X	Xc	X	Xc	Xc	X	X
Blood Sample for DNA			37	X				37		37		37		37		37	37	3.7k	3 70
Clinical Laboratory Assessments			X					X		X		X		X		X	X	X ^k	Xg
Biomic blood sample				Xf	X	Xf	X	Xf	X	Xf	X	Xf	X	Xf	X	Xf	*Xf	Xf	
PBMC blood sample				X		X			X		X		X		X				
MDS-UPDRS (including Hoehn & Yahr)h			X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	
Modified Schwab & England ADL			X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	
MDS-UPDRS Repeat Part III/Hoehn & Yahr ^j								X		X		X		X			X		
Clinical Diagnosis Assessments			X	X	X	X	X	X	X	X	X	X	X	X			X	X	
Physical Activity Scale for the Elderly (PASE)				X				X		X		X		X		X	X		
Hopkins Verbal Learning Test – Revised				X				X		X		X		X		X	X	X^k	
Benton Judgment of Line Orientation				X				X		X		X		X		X	X	X^k	
Semantic Fluency				X				X		X		X		X		X	X	X^k	
Letter Number Sequencing				X				X		X		X		X		X	X	X^k	
Symbol Digit Modalities Test				X				X		X		X		X		X	X	X^k	
Montreal Cognitive Assessment (MoCA)			X					X		X		X		X		X	X	X^k	
Epworth Sleepiness Scale				X		X		X		X		X		X		X	X	X	
REM Sleep Behavior Questionnaire				X		X		X		X		X		X		X	X	X	
Geriatric Depression Scale (GDS-15)			X			X		X		X		X		X		X	X	X	
State-Trait Anxiety Inventory for Adults			X			X		X		X		X		X		X	X	X	
QUIP				X		X		X		X		X		X		X	X	X	
SCOPA-AUT				X		X		X		X		X		X		X	X	X	
Cognitive Categorization				X		X		X		X		X		X		X	X	X^k	
Lumbar puncture (CSF collection)				X		X		X		X		X		X		X	*X	X^k	
MRI (structural)				X															
MRI (DTI) ^e				X				X		X							^X		

November 20, 2017/Amendment 13 Page 21 of 126

DAT imaging ^o		X					X		X		X		X			^X	X^k	
VMAT-2 imaging ^{m,o} , (see companion protocol)		X^q					X		X							^X	X^k	
[18F] florbetaben PET imaging (see companion protocol) ^s							X		(X)		(X)		(X)			$(X)^+$		
Adverse Events ^a		X	X		X		X		X		X		X		X	X	X	
Current Medical Conditions Review			X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Concomitant Medication Review		X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Skin Biopsy ^t (see companion protocol)				X (-	+ follo	w up c	all wit	hin 7-1	0 days	of bio	psy)							X
Blood draw ^t										X								
Sensor-PPMI activities (see companion protocol)	X																	

Schedule of Activities – Prodromal Subjects

- ^a Adverse events assessed at the visit and by phone 7 to 10 days following LP and/or DaTSCAN injection and following [¹⁸F] florbetaben PET imaging (for participating sites).
- ^b Telephone contact will occur at Months 15, 21, 27, 33, 39, 45, 51 and 57.
- ^c Height and weight also collected.
- ^e Diffusion tensor MRI scan and resting state sequences conducted at selected sites.
- f Biomic urine sample also collected.
- ^g Conduct as clinically indicated see protocol Sect. 5.3.18.
- ^h Part IV once subject has started PD medication.
- ^j Repeat assessment 1hr post treatment for subjects on levodopa or dopamine agonist.
- ^k Not conducted depending on when ST visit completed see protocol Sect. 5.3.20.
- † Intent to Donate documentation completed with PPMI Brain and Tissue Bank study team or local PPMI site based on accessibility, local regulations and availability of infrastructure. For subjects who have not yet been approached concerning the Brain and Tissue Bank, please review subject interest in providing permission to forward their contact information to the PPMI Brain and Tissue Bank study team at their next visit (including interim visits). For subjects who may have already been approached concerning the Brain and Tissue Bank, but were undecided concerning participation or who have not yet signed an Intent to Donate formplease review Brain and Tissue Bank with subject at next annual visit (sites may also review this at interim visits if site deems appropriate).

- ^m DAT completed in all sites except Australia; VMAT completed in Australia and selected U.S. sites.
- ^o Urine (or serum) pregnancy test prior to injection for women of childbearing potential.
- ^p Completed based on recruitment method
- ^q Serum pregnancy test prior to injection day for women of childbearing potential.
- ^s [¹⁸F] florbetaben PET imaging at selected sites (see companion protocol) at either Months 12, 24, 36, or 48
- ¹ Skin biopsy for participating sites completed at any routine or unscheduled visit post amendment approval; for sites collecting blood samples as part of companion study, blood draw completed at unscheduled visit or interim visit post amendment approval. (sites completing collection of blood sample at interim visit must forego collection of PBMCs and biomic blood samples at interim visit)

ST = Symptomatic Therapy;

PW = Premature Withdrawal (*if not done in last 3 mths; ^if not done in last 12 mths; ⁺if subject has not completed scan and is willing to complete at PW visit)

For active subjects, begin at next visit post amendment approval and consent

Perform at month 36 visit or later visit if subject has already completed month 36 visit.

Schedule of Activities - Genetic Cohort: PD subjects [Please see modified Schedule of Activities on page 28 for post month 60 visits]

Schedule of Activities – Gen						1	Teres o	puge		post		00 110	100		1	
	Visit Number	SC	BL	V02	V04 ^b	V05b	490Л	V07b	480A	460A	V10 ^b	V11b	V12	PW	ST	Unsch. Visit
Visit Description	Months (±30 days)	-45 days	0	6	12	18	24	30	36	42	48	54	60			
Written Informed Consent		X														
Consent/Withdrawal of Consent for Future Procedures#		X	X	X	X	X	X	X	X	X	X	X	X	X	X	
Advance Directive/Review Continuing Ability to Conse	ent#	X	X	X	X	X	X	X	X	X	X	X	X	X		X
Consent to Share Contact Information (FOUND in PPM	II companion protocol)#	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Consent to Share Contact Information with PPMI Brain Directive for PPMI Brain and Tissue Bank #†	and Tissue Bank/Advance	X		X	X	X	X	X	X	X	X	X	X	X	X	X
Consent/Withdrawal of Consent for Future Contact		X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Review Inclusion/Exclusion Criteria		X	X													
Medical History/Demographics		X														
Family History of PD Review		X	X	X	X	X	X	X	X	X	X	X	X	X	X	
Family History Substudy (see companion protocol)#			X													
Physical Examination		X														
Neurological Examination		X			X		X		X		X		X	X	Xk	Xg
Vital Signs		X	Xc	X	Xc	X	Xc	X	Xc	X	Xc	X	Xc	Xc	X	X
Blood Sample for DNA [®]		X														
Clinical Laboratory Assessments		X			X		X		X		X		X	X	Xk	Xg
Biomic blood sample			Xf	Xf	Xf	X	Xf	X	Xf	X	Xf	X	Xf	*Xf	Xf	
PBMC blood sample			X	X		X		X		X		X				
MDS-UPDRS (including Hoehn & Yahr) ^h		X	X	X	X	X	X	X	X	X	X	X	X	X	X	
Modified Schwab & England ADL		X	X	X	X	X	X	X	X	X	X	X	X	X	X	
Clinical Diagnosis Assessment(s)		X		X	X	X	X	X	X	X	X	X	X	X	X	
MDS-UPDRS Repeat Part III/Hoehn & Yahr ^j			X		X		X		X		X		X	X		
Physical Activity Scale for the Elderly (PASE)			X		X		X		X		X		X	X		
Hopkins Verbal Learning Test – Revised			X		X		X		X		X		X	X	Xk	
Benton Judgment of Line Orientation			X		X		X		X		X		X	X	X^k	
Semantic Fluency			X		X		X		X		X		X	X	X^k	
Letter Number Sequencing			X		X		X		X		X		X	X	X^k	
Symbol Digit Modalities Test			X		X		X		X		X		X	X	X^k	
Montreal Cognitive Assessment (MoCA)		X			X		X		X		X		X	X	X^k	
Epworth Sleepiness Scale			X	X	X		X		X		X		X	X	X	
REM Sleep Behavior Questionnaire			X	X	X		X		X		X		X	X	X	
Geriatric Depression Scale (GDS-15)			X	X	X		X		X		X		X	X	X	
State-Trait Anxiety Inventory for Adults			X	X	X		X		X		X		X	X	X	
QUIP			X	X	X		X		X		X		X	X	X	
SCOPA-AUT			X	X	X		X		X		X		X	X	X	
Cognitive Categorization			X	X	X		X		X		X		X	X	Xk	
Olfactory Testing (UPSIT)			X													
MRI (structural)			X													
MRI (DTI) ^e			X				X				X			^X		
DAT imaging ^{m,o}		X					X				X			^X	X^k	
VMAT-2 imaging ^{m,o, r} (see companion protocol)		Xp					X				X			^X	X^k	

November 20, 2017/Amendment 13

Lumbar puncture (CSF collection)		X		X		X		X		X		X	*X	X^k	
[18F] florbetaben PET imaging (see companion protocol) ^s				X		(X)		(X)		(X)		(X)	(X) +		
Adverse Events ^a	X	X		X		X		X		X		X	X	X	
Current Medical Conditions Review		X	X	X	X	X	X	X	X	X	X	X	X	X	X
Concomitant Medication Review	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Skin biopsy ^t (see companion protocol)				X (+	follow i	up call	within 1	7-10 da	ys of bi	iopsy)					X
Blood draw ^t															X
Gait assessments (see companion protocol) ^x		(X)		(X)		(X)		(X)		(X)		(X)			
Sensor-PPMI activities (see companion protocol)	X														

Schedule of Activities - Genetic Cohort (PD)

- ^a Adverse events assessed at the visit and by phone 7 to 10 days following LP and/or DaTSCAN injection and following skin biopsy and/or [¹⁸F] florbetaben PET imaging (for participating sites).
- ^b Telephone contact will occur at Months 15, 21, 27, 33, 39, 45, 51 and 57.
- ^c Height and weight also collected.
- ^e Diffusion tensor MRI scan and resting state sequences conducted at selected sites.
- f Biomic urine sample also collected.
- ^g Conduct as clinically indicated see protocol Sect. 5.3.18.
- ^h Part IV once subject has started PD medication.
- ^j Repeat assessment 1hr post treatment for subjects on levodopa or dopamine agonist.
- ^k Not conducted depending on when ST visit completed see protocol Sect. 5.3.20.
- ^mDAT completed at all sites except Australia; VMAT completed in Australia and selected U.S. sites.
- ^o Urine (or serum) pregnancy test prior to injection for women of childbearing potential.
- ^p Serum pregnancy test prior to injection day for women of childbearing potential; ECG for all subjects.
- Subjects enrolled in U.S. may agree to initial VMAT imaging scan at YR01 rather than Screening.

please review Brain and Tissue Bank with subject at next annual visit (sites may also review this at interim visits if site deems appropriate).

- ^s[¹⁸F] florbetaben PET imaging at selected sites (see companion protocol) at either Months 12, 24,or 36, 48, or 60
- ^t Skin biopsy for participating sites completed at any routine or unscheduled visit post-Amendment 8 approval. Genetic cohort subjects must be positive for LRRK2, GBA or SNCA mutation. For sites collecting blood samples as part of companion study, blood draw completed at unscheduled visit or interim visit post amendment approval. (sites completing collection of blood sample at interim visit must forego collection of PBMCs and biomic blood samples at interim visit)
- x Gait assessments at selected sites (see companion protocol); two gait assessments completed- first gait assessment completed at annual visit during which subject consents to gait assessment protocol; second gait assessment completed during subsequent regularly scheduled annual visit ST = Symptomatic Therapy
- PW = Premature Withdrawal (*if not done in last 3 mths; ^if not done in last 12 mths; ⁺if subject has not completed scan and is willing to complete at PW)
- [®] May be done at BL if not at SC
- # For active subjects, begin at next visit post amendment approval and consent

[†] Intent to Donate documentation completed with PPMI Brain and Tissue Bank study team or local PPMI site based on accessibility, local regulations and availability of infrastructure. For subjects who have not yet been approached concerning the Brain and Tissue Bank, please review subject interest in providing permission to forward their contact information to the PPMI Brain and Tissue Bank study team at their next visit (including interim visits). For subjects who may have already been approached concerning the Brain and Tissue Bank, but were undecided concerning participation or who have not yet signed an Intent to Donate form-

Schedule of Activities - Genetic Cohort: Unaffected Subjects [Please see modified Schedule of Activities on page 30 for post month 60 visits]

Schedule of Act	ivities – Genetic Cohort: Unaffected S	ubjects	Li icasc	See mod	illieu sc	lieuule u	ACUVI	ties on p	Jage 30 I	tor post	monun (JU VISIUS	1	1	
	Visit Number	SC	BL	V02	V04 ^b	V05b	_q 90Λ	МО7	480V	460A	V10 ^b	V11b	V12	PW	Unsch. Vist
Visit Description	Months (±30 days)	-45 days	0	6	12	18	24	30	36	42	48	54	60		
Written Informed Consent		X													
Consent/Withdrawal of Consent for Futi	ure Contact#	X	X	X	X	X	X	X	X	X	X	X	X	X	
Advance Directive/ Review Continuing	Ability to Consent#	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Consent to Share Contact Information (I protocol)#	FOUND in PPMI companion	X	X	X`	X	X	X	X	X	X	X	X	X	X	X
Consent to Share Contact Information w Bank/Advance Directive for PPMI Brain		X		X	X	X	X	X	X	X	X	X	X	X	X
Review Inclusion/Exclusion Criteria		X	X												
Medical History/Demographics		X													
Family History of PD Review		X	X	X	X	X	X	X	X	X	X	X	X	X	
Family History Substudy (see companio	n protocol)#		X												
Physical Examination	•	X													
Neurological Examination		X			X		X		X		X		X	X	Xg
Vital Signs		X	Xc	X	Xc	X	Xc	X	Xc	X	Xc	X	Xc	Xc	X
Blood Sample for DNA [@]		X													
Clinical Laboratory Assessments		X			X		X		X		X		X	X	Xg
Biomic blood sample			Xf	X^{f}	Xf	X	Xf	X	X^{f}	X	Xf	X	X^{f}	*Xf	
PBMC blood sample			X	X		X		X		X		X			
MDS-UPDRS (including Hoehn & Yahr	r) ^h	X	X	X	X	X	X	X	X	X	X	X	X	X	
Modified Schwab & England ADL		X	X	X	X	X	X	X	X	X	X	X	X	X	
Clinical Diagnosis Assessment(s)		X		X	X	X	X	X	X	X	X	X	X	X	
MDS-UPDRS Repeat Part III/Hoehn &			X		X		X		X		X		X	X	
Physical Activity Scale for the Elderly (PASE)		X		X		X		X		X		X	X	
Hopkins Verbal Learning Test – Revised	d		X		X		X		X		X		X	X	
Benton Judgment of Line Orientation			X		X		X		X		X		X	X	
Semantic Fluency			X		X		X		X		X		X	X	
Letter Number Sequencing			X		X		X		X		X		X	X	
Symbol Digit Modalities Test			X		X		X		X		X		X	X	
Montreal Cognitive Assessment (MoCA	A)	X			X		X		X		X		X	X	
Epworth Sleepiness Scale			X	X	X		X		X		X		X	X	
REM Sleep Behavior Questionnaire			X	X	X		X		X		X		X	X	
Geriatric Depression Scale (GDS-15)			X	X	X		X		X		X		X	X	
State-Trait Anxiety Inventory for Adults	S		X	X	X		X		X		X		X	X	ļ
QUIP			X	X	X		X		X		X		X	X	
SCOPA-AUT			X	X	X		X		X		X		X	X	
Cognitive Categorization			X	X	X		X		X		X		X	X	
Olfactory Testing (UPSIT)			X		ļ			ļ	X>	ļ	ļ	ļ	X	ļ	ļ
MRI (structural)			X											4	
MRI (DTI) ^e			X		l		X	l		l	X			^X	

DAT imaging ^{m,o}	X					X				X			^X	
VMAT-2 imaging ^{m,o, r} (see companion protocol)	Xp					X				X			^X	
Lumbar puncture (CSF collection)		X		X		X		X		X		X	*X	
[18F] florbetaben PET imaging (see companion protocol) ^s				X		(X)		(X)		(X)		(X)	$(X)^+$	
Adverse Events ^a	X	X		X		X		X		X		X	X	
Current Medical Conditions Review		X	X	X	X	X	X	X	X	X	X	X	X	X
Concomitant Medication Review	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Skin Biopsy ^t (see companion protocol)		X (+ follow up call within 7-10 days of biopsy)									X			
Blood draw ^t														X
Gait assessments (see companion protocol) ^x		(X)		(X)		(X)		(X)		(X)		(X)		

Schedule of Activities – Genetic Cohort: Unaffected Subjects

- ^a Adverse events assessed at the visit and by phone 7 to 10 days following LP and/or DaTSCAN injection and following skin biopsy and/or [¹⁸F] florbetaben PET imaging (for participating sites).
- ^b Telephone contact will occur at Months 15, 21, 27, 33, 39, 45, 51 and 57.
- ^c Height and weight also collected.
- ^e Diffusion tensor MRI scan and resting state sequences conducted at selected sites.
- ^f Biomic urine sample also collected.
- ^g Conduct as clinically indicated see protocol Sect. 5.3.18.
- h Part IV once subject has started PD medication
- ^j Repeat assessment 1hr post treatment for subjects on levodopa or dopamine agonist.
- ^k Not conducted depending on when ST visit completed see protocol Sect. 5.3.20.
- ^mDAT completed at all sites except Australia; VMAT completed in Australia and selected U.S. sites.
- ^o Urine (or serum) pregnancy test prior to injection for women of childbearing potential.
- ^p Serum pregnancy test prior to injection day for women of childbearing potential; ECG for all subjects.
- ^r Subjects enrolled in U.S. may agree to initial VMAT imaging scan at YR01 rather than Screening.
- [@] May be done at BL if not at SC
- ^s[¹⁸F] florbetaben PET imaging at selected sites (see companion protocol) at either Months 12, 24, 36, 48, or 60
- ^t Skin biopsy for participating sites completed at any routine or unscheduled visit post-amendment approval; for sites collecting blood samples as part of companion study, blood draw completed at unscheduled visit or interim visit post amendment approval. (sites completing collection of blood sample at interim visit must forego collection of PBMCs and biomic blood samples at interim visit) ^x Gait assessments at selected sites (see companion protocol); two gait assessment completed- first gait assessment completed at annual visit during which subject consents to gait assessment protocol; second gait assessment completed during subsequent regularly scheduled annual visit

PW = Premature Withdrawal (*if not done in last 3 mths; ^if not done in last 12 mth; †if subject has not completed scan and is willing to complete at PW)

For active subjects, begin at next visit post amendment approval and consent

> Perform at month 36 visit or later visit if subject has already completed month 36 visit.

† Intent to Donate documentation completed with PPMI Brain and Tissue Bank study team or local PPMI site based on accessibility, local regulations and availability of infrastructure. For subjects who have not yet been approached concerning the Brain and Tissue Bank, please review subject interest in providing permission to forward their contact information to the PPMI Brain and Tissue Bank study team at their next visit (including interim visits). For subjects who may have already been approached concerning the Brain and Tissue Bank, but were undecided concerning participation or who have not yet signed an Intent to Donate form- please review Brain and Tissue Bank with subject at next annual visit (sites may also review this at interim visits if site deems appropriate).

PPMI Study 001

Schedule of Activities – Genetic Registry Subjects*

CONFIDENTIAL

		chedule (of Activiti	es – Gen	euc Kegi	stry Subje	ecis"	1	1				1	1
	Visit Number	SC/BSL	PV02	PV04	PV05	90Ad	PV07	PV08	PV09	PV10	PV11	PV12	PW	Unsch. Visit
Visit Description	Months (±30 days)	0	6	12	18	24	30	36	42	48	54	60		
Written Informed Consent		X												
Consent/Withdrawal of Consent for	r Future Contact [#]	X	X	X	X	X	X	X	X	X	X	X	X	X
Advance Directive/Continuing Abi	lity to Consent#	X												X
Consent to Share Contact Informati protocol)#		X	X	X	X	X	X	X	X	X	X	X	X	X
Consent to Share Contact Informati Bank /Advance Directive for PPMI		X	X	X	X	X	X	X	X	X	X	X	X	X
Review Inclusion/Exclusion Criteri	ia	X												
Medical History/Demographics		X												
Family History of PD Review		X	X	X	X	X	X	X	X	X	X	X	X	
Family History Substudy (see comp	panion protocol)#	X												
Physical Examination		X												
Neurological Examination		X												Xg
Vital Signs		X c												X
Blood Sample for DNA		X												
Clinical Laboratory Assessments		X												Xg
Biomic blood sample		X f												
Olfactory Testing (UPSIT)		X												
MDS-UPDRS (including Hoehn &	Yahr) ^h	X												
Modified Schwab & England ADL		X												
Clinical Diagnosis Assessment(s)		X												Xg
Clinical Diagnosis Review			X	X	X	X	X	X	X	X	X	X	X	
MDS-UPDRS Repeat Part III/Hoeh	ın & Yahr ^j													
Montreal Cognitive Assessment (M	IoCA)	X												
REM Sleep Behavior Questionnaire	e	X												
Current Medical Conditions Review	N		X	X	X	X	X	X	X	X	X	X	X	X
Concomitant Medication Review		X	X	X	X	X	X	X	X	X	X	X	X	X
C Haight and waight also collected			Dhone Vie		•	•								

^c Height and weight also collected.

or who have not yet signed an Intent to Donate form- please review Brain and Tissue Bank with subject at next annual visit (sites may also review this at interim visits if site deems appropriate).

^f Biomic urine sample also collected.

^g Conduct as clinically indicated – see protocol Sect. 5.3.18.

^h Part IV once subject has started PD medication.

[#] For active subjects, begin at next visit post amendment approval and consent

PV= Phone Visit

PW = Premature Withdrawal

^{*} With amendment 13 approval, Genetic Registry subjects will complete one final phone visit, and then discontinue visits j Repeat assessment 1hr post treatment for subjects on levodopa or dopamine agonist.

[†] Intent to Donate documentation completed with PPMI Brain and Tissue Bank study team or local PPMI site based on accessibility, local regulations and availability of infrastructure. For subjects who have not yet been approached concerning the Brain and Tissue Bank, please review subject interest in providing permission to forward their contact information to the PPMI Brain and Tissue Bank study team at their next visit (including interim visits). For subjects who may have already been approached concerning the Brain and Tissue Bank, but were undecided concerning participation

Modified Schedule of Activities- Parkinson's Disease, Healthy Controls and PD Genetic Cohort Subjects- Post Month 60 or Post January 1, 2019 visits

Modified Schedule of Activities-			l s Disc.	usc, mean	tily con		CEL	CHC CON		103		00 01 10	Junua	1 1, 201	7 15165		
	Visit number	V13	P13	V14	P14	V15	P15	V16	P16	V17	P17	V18	P18	V19	P19	V20	PW visit
Visit Description	Months (+30 days)	72	78	84	90	96	102	108	114	120	126	132	138	144	150	156	
Consent/Withdrawal of Consent for Future Procedures		X		X		X		X		X		X		X		X	X
Advance Directive/Review Continuing Ability to Consent		X		X		X		X		X		X		X		X	X
Consent to Share Contact Information (FOUND in PPMI companion protocol)		X ⁺	X ⁺	X^+	X^+	X ⁺	X ⁺	X ⁺	X ⁺	X ⁺	X ⁺	X ⁺	X ⁺	X ⁺	X^+	X ⁺	X ⁺
Consent to Share Contact Information with PPMI Brain and Tissue Bank /Advance Directive for PPMI Brain and Tissue Bank		X ⁺	X ⁺	X ⁺	X^+	X ⁺	X ⁺	X ⁺	X ⁺	X ⁺	X ⁺	X ⁺	X ⁺	X ⁺	X ⁺	X ⁺	X ⁺
Vital Status			X		X		X		X		X		X		X		
Confirm/Update Subject C	Contact Information		X		X		X		X		X		X		X		
Medical & Family History/Demographics		X		X		X		X		X		X		X		X	X
Vital Signs		X		X		X		X		X		X		X		X	X
Biomic blood sample (no urine)		X		X		X		X		X		X		X		X	X
PBMC (assuming volume acceptable)		X		X		X		X		X		X		X		X	X
MDS-UPDRS (including Hoehn & Yahr)^		X		X		X		X		X		X		X		X	X
Modified Schwab & England ADL ^a		X		X		X		X		X		X		X		X	X
Clinical Diagnosis Assessment(s)		X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
MDS-UPDRS Repeat Par	t III/Hoehn & Yahr #	X		X		X		X		X		X		X		X	X
Physical Activity Scale fo	r the Elderly (PASE)	X		X		X		X		X		X		X		X	X
Hopkins Verbal Learning	Test – Revised	X		X		X		X		X		X		X		X	X
Benton Judgment of Line	Orientation	X		X		X		X		X		X		X		X	X
Semantic Fluency (Anima	ıls only)	X		X		X		X		X		X		X		X	X
Letter Number Sequencin	g	X		X		X		X		X		X		X		X	X
Symbol Digit Modalities	Гest	X		X		X		X		X		X		X		X	X
Lexical Fluency (FAS)		X		X		X		X		X		X		X		X	X
Boston Naming Test		X		X		X		X		X		X		X		X	X
Montreal Cognitive Assessment (MoCA)		X		X		X		X		X		X		X		X	X
Epworth Sleepiness Scale		X		X		X		X		X		X		X		X	X
REM Sleep Behavior Questionnaire		X		X		X		X		X		X		X		X	X
Geriatric Depression Scale	e (GDS-15)	X		X		X		X		X		X		X		X	X
State-Trait Anxiety Invent	tory for Adults	X		X		X		X		X		X		X		X	X

QUIP	X	X	X	X	X	X	X	X	X
SCOPA-AUT	X	X	X	X	X	X	X	X	X
Cognitive Categorization	X	X	X	X	X	X	X	X	X
Trails A & B	X	X	X	X	X	X	X	X	X
Determination of Falls	X	X	X	X	X	X	X	X	X
NeuroQOL	X	X	X	X	X	X	X	X	X
Olfactory Testing (UPSIT)	X	X	X	X	X	X	X	X	X
Lumbar puncture (CSF collection)		X		X		X		X	X*
Adverse Events ~		X~		X~		X~		X~	X~
Current Medical Conditions Review	X	X	X	X	X	X	X	X	X
Concomitant Medication Review	X	X	X	X	X	X	X	X	X

^{*} If not done in last 3 months

~ Adverse events assessed at visit and 7 to 10 days following LP (when LP completed as part of a visit)

Repeat assessment 1hr post treatment for subjects on levodopa or dopamine agonist

+ If subject has not previously consented to contact with PPMI Pathology Core or FOUND in PPMI team

P= Phone visit

 $PW = Premature \ Withdrawal$

[^] Part IV once subject has started PD medication

^a Healthy Control subjects will not complete the Modified Schwab and England ADL

Modified Schedule of Activities- Prodromal and Unaffected Genetic Cohort Subjects- Post Month 60 or Post January 1, 2019 visits Visit number V13 P13 P14 P15 P16 V17 P17 P18 V19 PW visit PV visit 72 Visit Description Months (+30 days) 78 84 102 108 114 120 126 132 138 144 150 156 X X X X X X Consent/Withdrawal of Consent for Future Procedures X X X X X X X X X X X X X Advance Directive/Review Continuing Ability to Consent Consent to Share Contact Information (FOUND in PPMI X^{+} X^{+} $X^{\scriptscriptstyle +}$ X^{+} X^{+} $X^{\scriptscriptstyle +}$ X^{+} X^{+} $X^{\scriptscriptstyle +}$ X^{+} X^+ X^{+} $X^{\scriptscriptstyle +}$ $X^{\scriptscriptstyle +}$ X^{+} X^{+} X^{+} companion protocol) X^{+} Consent to Share Contact Information with PPMI Pathology Core X^{+} X X X X X X Vital Status X X X X X X X Confirm/Update Subject Contact Information X X X X X X X X X X X X X X X X X Participant Questionnaire/Self-Report UPSIT X X X X X X Medical & Family History/Demographics X X X X X X X X X X Self-reporting questionnaire X X X X X X X X X X X X X X X X X X X Neurological Examination Vital Signs X X X X X X X X X X Biomic blood sample (no urine) X X X X X X X X X PBMC Blood sample X X X X X X X X X X X X X MDS-UPDRS (including Hoehn & Yahr) ^ X X X X X X X X X Modified Schwab & England ADL X X X X X X X X X X X X MDS-UPDRS Repeat Part III/Hoehn & Yahr # X X X X X X X X X X X X X X X X Clinical Diagnosis Assessments Χ X X X X X X X X X X X Physical Activity Scale for the Elderly (PASE) X X X X X X X X X Hopkins Verbal Learning Test - Revised X X X X X X X X X X X X X X X Benton Judgment of Line Orientation X X X X X X X X X X Semantic Fluency-Animals only X X X X X X X Letter Number Sequencing X X X Symbol Digit Modalities Test X X X X X Χ X X X X X X X X X X X X Lexical Fluency (FAS) X X X X X X X Boston Naming Test (15 item) X X X X X X X X X X X X X X Montreal Cognitive Assessment X X X X X X X X X Epworth Sleepiness Scale X X X X X X X X X X **REM Sleep Behavior Questionnaire** X X X X X X X X X X Geriatric Depression Scale (GDS-15)

111111 5000 001								001	1 12 21 1	
State-Trait Anxiety Inventory for Adults	X	X	X	X	X	X	X	X	X	X
QUIP	X	X	X	X	X	X	X	X	X	X
SCOPA-AUT	X	X	X	X	X	X	X	X	X	X
Cognitive Categorization	X	X	X	X	X	X	X	X	X	X
Trails A & B	X	X	X	X	X	X	X	X	X	X
Determination of Falls	X	X	X	X	X	X	X	X	X	X
NeuroQOL	X	X	X	X	X	X	X	X	X	X
DAT imaging ^a										X
Lumbar puncture (CSF collection)		X		X		X		X	X*	X*
Adverse Events ~		X~		X~		X~		X~	X~	X~
Current Medical Conditions Review	X	X	X	X	X	X	X	X	X	X
Concomitant Medication Review	X	X	X	X	X	X	X	X	X	X

^{*} If not done in last 3 months

P= Phone visit

PW = Premature Withdrawal

PV=Phenoconversion visit

[~] Adverse events assessed at visit and 7 to 10 days following LP or DAT imaging (when LP or DAT imaging completed as part of a visit)

[^] Part IV once subject has started PD medication

[#] Repeat assessment 1hr post treatment for subjects on levodopa or dopamine agonist

a Urine (or serum) pregnancy test prior to injection for women of childbearing potential.

+ If subject has not previously consented to contact with PPMI Pathology Core or FOUND in PPMI team